Astrid Stawiarz / CNBCsimply click here to claim your deal and get access to all exclusive Business Insider PRIME content.Analysts from SVB Leerink rounded up the five best and the five worst pharma deals of the last decade.
One of the best deals was Merck acquiring Schering-Plough for $41 billion in 2009, with one of the worst deals being Johnson & Johnson's $30 billion acquisition of Actelion in 2017, according to the Leerink analystsOver the past 10 years, dealmaking has reshaped the pharmaceutical industry. Facing generic competition for once-blockbuster drugs and new pricing threats, many a deal got done to fill in key gaps in a company's portfolio — some more successfully than others.
Analysts at SVB Leerink rounded up the five best and the five worst acquisitions of the last decade. The list of best and worst deals are based on an analysis of all the transactions over the last decade along with the input of the SVB Leerink therapeutics research team, and it shines some light on the often binary nature of biotech dealmaking.
The analysts found overall that deals with a transaction value of $1 billion to $5 billion have the highest success rate, compared to lower success rates for larger transactions. The analysts note that deals within the oncology space had two times the success rate as deals in other therapeutic areas.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »